A novel antitumor piperazine alkyl compound causes apoptosis by inducing RhoB expression via ROS‑mediated c‑Abl/p38
Purpose:
We investigated the action mechanism of a novel anticancer compound, KR28 (1-allyl-4-dodecanoyl-1-ethyl-piperazin-1-ium; bromide), to induce apoptosis of human prostate carcinoma PC-3 cells.
Methods:
To explore an apoptotic signaling of KR28, we used ROS assay, SRB assay, flow cytometry analysis, reporter assay, xenograft assay, Western blotting, and RT-PCR analysis.
Results:
The growth inhibitory action of KR28 is cell line specific, impeding the growth of prostate carcinoma PC-3 and stomach carcinoma NUGC-3 cells. KR28 showed strong antitumor activity in PC-3 mouse xenograft model. KR28 increased ROS production, leading to nuclear c-Abl expression, which in turn activated p38 mitogen-activated protein kinase (MAPK) to enhance the expression of RhoB, an apoptosis inducer. The KR28-induced apoptosis was abrogated by the ROS scavenger N-acetylcysteine and by knockdown of c-Abl, p38 MAPK, or ATF2. Moreover, the p300 binding site and two CCAAT boxes in the RhoB promoter appear to be involved in ROS-mediated RhoB expression in the presence of KR28.
Conclusion:
The antitumor agent KR28 induces apoptosis of PC-3 cells by ROS-mediated RhoB expression via c-Abl upregulation and activation of p38 MAPK/ATF-2.
Insights
The novel anticancer compound KR28 induces apoptosis in prostate cancer cells by increasing reactive oxygen species (ROS) and activating specific signaling pathways. This leads to enhanced expression of RhoB, a key apoptosis inducer.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Prostate carcinoma is a significant health concern.
- Novel therapeutic strategies are needed to combat cancer.
- Understanding apoptosis induction mechanisms is crucial for drug development.
Purpose of the Study:
- To elucidate the mechanism of action of the novel anticancer compound KR28.
- To investigate how KR28 induces apoptosis in human prostate carcinoma PC-3 cells.
Main Methods:
- Cell viability assays (SRB assay).
- Apoptosis analysis (flow cytometry).
- Reactive oxygen species (ROS) detection.
- Gene expression analysis (Western blotting, RT-PCR).
- In vivo efficacy study (xenograft assay).
Main Results:
- KR28 demonstrated cell line-specific growth inhibition, notably in PC-3 cells.
- KR28 exhibited significant antitumor activity in a PC-3 xenograft mouse model.
- KR28 induced apoptosis via increased ROS production, leading to c-Abl expression and subsequent p38 MAPK/ATF-2 activation, enhancing RhoB expression.
Conclusions:
- KR28 triggers apoptosis in PC-3 cells through a ROS-dependent pathway.
- The mechanism involves c-Abl upregulation and p38 MAPK/ATF-2 activation, culminating in RhoB expression.
- This study provides insights into KR28's anticancer action, highlighting its potential therapeutic value.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:15Experimental RNAi
02:23Abnormal Proliferation